A comparative pharmacokinetics study of Ashwagandha (Withania somnifera) Root Extract sustained-release capsules: an open-label, randomized, two treatment, two-sequence, two period, single-dose crossover clinical study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20214831Keywords:
Withania somnifera, Withanolides, Ashwagandha, Sustained-release, PharmacokineticAbstract
Background: In this open-label, randomized, balanced, two-treatment, two-sequence, two-period, crossover, single-dose oral comparative pharmacokinetics study, the pharmacokinetics, safety, and tolerability of test product ‘ashwagandha (Withania somnifera)’ root extract sustained release capsule 300 mg (Prolanza™), each containing 15 mg withanolides (administered dose: 2×15 mg) was compared with that of a reference product (organic KSM-66 ashwagandha extract [vegan] capsule, each containing 15 mg withanolides [administered dose: 2×15 mg]).
Methods: Total 14 healthy men were randomized to receive either the test or the reference product as a single dose of 2 capsules in sequence, administered under fasting conditions. Plasma concentrations of total withanolides, withanolide A and 12-deoxywithastramonolide were measured using validated liquid chromatography–mass spectroscopy/mass spectroscopy.
Results: The test product had higher relative absorption, better relative bioavailability, and longer elimination half-life indicating a sustained-release profile compared to reference. Specifically, the relative bioavailability of the test formulation was 12, 44, and 11 times higher for total withanolides, withanolide A and 12-deoxywithastramonolide, respectively. No adverse events were reported during the study.
Conclusions: The sustained-release profile of the test product, compared to reference product, will provide more long-lasting therapeutic effects from a single daily dose (Retrospectively applied on Clinical Trials Registry - India [CTRI]. Application reference number: REF/2020/03/032408). The study reports the unique sustained release formulation of Withania somnifera (Ashwagandha) root extract. The pharmacokinetic study also reports for first time, the successful plasma estimation of withanolide A and 12-deoxywithastraamonolide, the major phytoactives of ashwagandha.
Metrics
References
Central Council for Research in Ayurveda and Siddha; Government of India; Department of AYUSH. Ashwagandha, In the Ayurvedic pharmacopoeia of India, AYUSH: New Delhi, India. 2008;1(1):19-20.
Balasubramani SP, Venkatasubramanian P, Kukkupuni SK, Patwardhan B. Plant-based Rasayana drugs from Ayurveda. Chin J Integr Med. 2011;17(2):88-94.
Singh N, Bhalla M, De Jager P, Gilca M. An overview on ashwagandha: A Rasayana (Rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5S):208-13.
Verma SK, Kumar A. Therapeutic uses of Withania somnifera (ashwagandha) with a note on withanolides and its pharmacological actions. Asian J Pharm Clin Res. 2011;4(1):1-4.
Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 2009;14(7):2373-93.
Girme A, Saste G, Pawar S, Balasubramaniam AK, Musande K, Darji B, et al. Investigating 11 withanosides and Withanolides by UHPLC-PDA and Mass Fragmentation Studies from Ashwagandha (Withania somnifera). ACS omega. 2020;5(43):27933-43.
Tohda C, Kuboyama T, Komatsu K. Search for natural products related to regeneration of the neuronal network. Neurosignals, 2005;14(1-2):34-45.
Dhanani T, Shah S, Gajbhiye N, Kumar S. Effect of extraction methods on yield, phytochemical constituents and antioxidant activity of Withania somnifera. Arab J Chem. 2017;10:S1193-9.
Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255-62.
Choudhary D, Bhattacharyya S, Bose S. Efficacy and safety of Ashwagandha (Withania somnifera (L.) Dunal) root extract in improving memory and cognitive functions. J Diet Suppl. 2017;14(6):599-612.
Pingali U, Pilli R, Fatima N. Effect of standardized aqueous extract of Withania somnifera on tests of cognitive and psychomotor performance in healthy human participants. Pharmacogn Res. 2014;6(1):12-8.
Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). J Altern Complement Med. 2014;20(12):901-8.
Lopresti AL, Drummond PD, Smith SJ. A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males. Am J Mens Health. 2019;13(2):1557988319835985.
Dongre S, Langade D, Bhattacharyya S. Efficacy and safety of Ashwagandha (Withania somnifera) root extract in improving sexual function in women: a pilot study. Biomed Res Int. 2015;284154:1-9.
Mamidi P, Thakar A. Efficacy of Ashwagandha (Withania somnifera Dunal. Linn.) in the management of psychogenic erectile dysfunction. Ayu. 2011;32(3):322-8.
Ziegenfuss TN, Kedia AW, Sandrock JE, Raub BJ, Kerksick CM, Lopez HL. Effects of an aqueous extract of Withania somnifera on strength training adaptations and recovery: The STAR Trial. Nutrients. 2018;10(11):1807.
Kumar G, Srivastava A, Sharma SK, Rao TD, Gupta YK. Efficacy safety evaluation of Ayurvedic treatment (Ashwagandha powder and Sidh Makardhwaj) in rheumatoid arthritis patients: a pilot prospective study. Indian J Med. Res. 2015;141(1):100-6.
Kumar R, Rai J, Kajal N, Devi P. Comparative study of effect of Withania somnifera as an adjuvant to DOTS in patients of newly diagnosed sputum smear positive pulmonary tuberculosis. Indian J Tuberc. 2018;65(3):246-51.
Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. 2013;12(4):312-22.
Chengappa KR, Brar JS, Gannon JM, Schlicht PJ. Adjunctive use of a standardized extract of Withania somnifera (Ashwagandha) to treat symptom exacerbation in schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2018;79(5):17m11826.
Chen Z, Zhu Q, Qi J, Lu Y, Wu W. Sustained and controlled release of herbal medicines: The concept of synchronized release. Int J Pharm. 2019;560:116-25.
Wei Z, Li T, Su H, Wang Q, Kuang H. Pharmacological Effects of Withanolides. Biomed J Sci Tech Res. 2020;25(3):19243-8.
Patil D, Gautam M, Mishra S, Karupothula S, Gairola S, Jadhav S et al. Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. J Pharm Biomed Anal. 2013;80:203-12.
Dai T, Jiang W, Guo Z, Wang Z, Huang M, Zhong G et al. Studies on oral bioavailability and first‐pass metabolism of withaferin A in rats using LC-MS/MS and Q‐TRAP. Biomed Chromatogr. 2019;33(9):e4573.
Wang F, Zhao J, Bai J, Gao K, Cui D et al. Liquid chromatography-tandem mass spectrometry to assess pharmacokinetics and tissue distribution of withaferin A in rats. J Chromatogr A. 2019;1122:90-5.
Yang L, Meng X, Kuang H. Comparisons of the pharmacokinetic and tissue distribution profiles of withanolide B after intragastric administration of the effective part of Datura metel L. in normal and psoriasis guinea pigs. J Chromatogr A. 2018;1083:284-8.
Dahikar PR, Kumar N, Sahni Y. Pharmacokinetics of Withania somnifera (Ashwagandha) in healthy buffalo calves. Buffalo Bull. 2012;31(4):219-23.
Pires N, Gota V, Gulia A, Hingorani L, Agarwal M, Puri A. Safety and Pharmacokinetics of Withaferin-A in advanced stage high grade Osteosarcoma: A phase I trial. J Ayurveda Integr Med. 2020;11(1):68-72.
Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J. 2011;32(3):264-8.
